Last reviewed · How we verify
NCT06262620
The Comparison of EBUS-TBNA, TBMC Via a Tunnel, and TBFB Via a Tunnel in Diagnosing Mediastinal Lymphadenopathy.
NA trial testing EBUS-TBNA in Lymphadenopathy Hilar in 552 participants. Currently enrolling.
18 February 2026
Quick facts
| Lead sponsor | China-Japan Friendship Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 552 |
| Start date | 1 March 2024 |
| Primary completion | 18 February 2026 |
| Estimated completion | 18 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- EBUS-TBNA
- EBUS-TBMC via a tunnel
- EBUS-TBFB via a tunnel
Conditions studied
- Lymphadenopathy Hilar — all drugs for Lymphadenopathy Hilar →
- Lymphadenopathy Mediastinal — all drugs for Lymphadenopathy Mediastinal →
Sponsor
China-Japan Friendship Hospital
Who can join
18 and older, any sex, with Lymphadenopathy Hilar or Lymphadenopathy Mediastinal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this prospective, multi-centre, randomised controlled clinical study is to compare the diagnostic yield and safety of the three biopsy techniques (EBUS-TBNA, EBUS-TBMC via a tunnel, and EBUS-TBFB via a tunnel) in mediastinal/hilar lymph node biopsies. Participants will divided into EBUS-TBNA group, EBUS-TBMC via a tunnel group, and EBUS-TBFB via a tunnel group at a 1:1:1 ratio by using central, computerized random sequence, and then undertake EBUS-TBNA, EBUS-TBMC via a tunnel, or EBUS-TBFB according to the group. Researchers will compare the diagnostic yield and incidence of adverse events of the three biopsy techniques.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of diagnostic yield and safety of three endobronchial ultrasound-guided transbronchial biopsy techniques in diagnosing patients with mediastinal/hilar lymphadenopathy: a protocol of multicentre randomised trial in China.
Deng MM, Yang Z, Zhong C, Zheng Z, et al · · 2025 · cited 1× · PMID 40987727 · DOI 10.1136/bmjopen-2024-096871
Verify or expand the search:
- PubMed search for NCT06262620
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EBUS-TBNA
Trials testing the same drug.
- NCT06913569 — EBUS-TTFB vs EBUS-TBNA for Diagnosing Inadequate Lymph Node Specimens Based on MOSE · NA · recruiting
- NCT05840094 — Multimodalitic Imaging in the N-stage of Lung Cancer · NA · unknown
- NCT05803239 — Study on Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy Via a Tunnel in the Diagnosis of Mediasti · NA · completed
- NCT04200105 — EBUS-TBNA vs Acquire TBNB · NA · unknown
- NCT03017183 — Detection of Heterogeneity in Central Lung Cancer - EBUS-TBNA and ctDNA Analysis vs. Endobronchial Forceps Biopsy · NA · completed
Other China-Japan Friendship Hospital trials
Trials by the same sponsor.
- NCT07482995 — Effects of Baduanjin Exercise on Improving Health in Sedentary Young and Middle-Aged Adults · NA · not yet recruiting
- NCT07406932 — A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial L · NA · not yet recruiting
- NCT07509775 — Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on · recruiting
- NCT07339956 — Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents · EARLY_PHASE1 · not yet recruiting
- NCT07280429 — ICIAM Rehabilitation Program Study: A Randomized Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06262620 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China-Japan Friendship Hospital
- Last refreshed: 27 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06262620.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing